Scientific Opinion on the substantiation of a health claim related to an equimolar mixture of the CLA isomers c9,t11 and t10,c12 (marketed as Clarinol® and Tonalin®) and “contributes to a reduction in body fat mass” pursuant to Article 13(5) of Regulation by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Nov 08, 2017
Scientific Opinion on the substantiation of a health claim related to an equimolar
mixture of the CLA isomers c9,t11 and t10,c12 (marketed as Clarinol® and Tonalin®)
and “contributes to a reduction in body fat mass” pursuant to Article 13(5) of
Regulation
Tetens, Inge; EFSA Journal
Link to article, DOI:
10.2903/j.efsa.2015.3953
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Journal (2015). Scientific Opinion on the substantiation of a health claim related to an equimolar mixture
of the CLA isomers c9,t11 and t10,c12 (marketed as Clarinol® and Tonalin®) and “contributes to a reduction in
body fat mass” pursuant to Article 13(5) of Regulation. Parma, Italy: Europen Food Safety Authority.  (The EFSA
Journal; No. 3953, Vol. 13(1)). DOI: 10.2903/j.efsa.2015.3953
  EFSA Journal 2015;13(1):3953 
 
Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015. Scientific Opinion 
on the substantiation of a health claim related to an equimolar mixture of the CLA isomers c9,t11 and t10,c12 (marketed as 
Clarinol® and Tonalin®) and “contributes to a reduction in body fat mass” pursuant to Article 13(5) of Regulation (EC) No 
1924/2006. EFSA Journal 2015;13(1):3953, 11 pp. doi:10.2903/j.efsa.2015.3953 
Available online: www.efsa.europa.eu/efsajournal 
 
© European Food Safety Authority, 2015 
SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to an 
equimolar mixture of the CLA isomers c9,t11 and t10,c12 (marketed as 
Clarinol
®
 and Tonalin
®
) and “contributes to a reduction in body fat mass” 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from BASF SE and Stepan Lipid Nutrition, submitted for the authorisation of a health 
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the 
Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an 
opinion on the scientific substantiation of a health claim related to an equimolar mixture (marketed under the 
trade names Clarinol
®
 and Tonalin
®
) of the two conjugated linoleic acid (CLA) isomers c9,t11 and t10,c12. The 
Panel considers that the food is sufficiently characterised. The claimed effect is “contributes to a reduction in 
body fat mass”. In previous assessments on the safety of these equimolar isomeric mixtures of CLA, the NDA 
Panel considered that the observed increase in plasma and urinary concentrations of isoprostanes, which may 
indicate an increase in lipid peroxidation, and the increase in some markers of subclinical inflammation 
associated with CLA consumption, together with the limited data available on the effects of CLA on vascular 
function, may indicate a potential for vascular damage in the longer term. The Panel considers that the 
information provided does not establish that a reduction in body fat mass, when accompanied by an increase in 
markers of lipid peroxidation and inflammation, is a beneficial physiological effect for the target population. The 
Panel concludes that a cause and effect relationship has not been established between the consumption of an 
equimolar mixture of the CLA isomers c9,t11 and t10,c12, marketed under the trade names of Clarinol
®
 and 
Tonalin
®
, and a beneficial physiological effect. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from BASF SE and Stepan Lipid Nutrition, submitted for the authorisation 
of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent 
Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to an 
equimolar mixture (marketed under the trade names of Clarinol
®
 and Tonalin
®
) of the two conjugated 
linoleic acid (CLA) isomers c9,t11 and t10,c12, and “contributes to a reduction in body fat mass”. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food that is the subject of the health claim is Clarinol
®
 or Tonalin
®
, which provide a minimum of 
78 % of total fatty acids as CLA and a minimum of 74 % of total fatty acids as the two CLA isomers 
cis-9,trans-11 (c9,t11) and trans-10,cis-12 (t10,c12) at an equimolar (1:1) ratio. The Panel considers 
that the food, an equimolar mixture of the CLA isomers c9,t11 and t10,c12, marketed under the trade 
names of Clarinol
®
 and Tonalin
®
, is sufficiently characterised. 
The claimed effect is “contributes to a reduction in body fat mass”. The target population proposed by 
the applicant is “healthy overweight or class I obese male and female adults, either sedentary or 
physically active, who wish to reduce their body fat mass”. The Panel notes that an excess of body fat, 
and in particular of abdominal fat, is associated with adverse health effects, e.g. impaired glucose 
tolerance, dyslipidaemia and high blood pressure. The Panel also notes that a reduction of body fat 
through energy (i.e. caloric) restriction and/or through an increase in energy expenditure (i.e. physical 
exercise/activity) is generally accompanied by an improvement of such adverse health effects. In this 
context, the Panel considers that a reduction of body fat, with or without a reduction of body weight, 
is a beneficial physiological effect for overweight subjects in the general population. 
In previous assessments on the safety of these equimolar isomeric mixtures (c9,t11 and t10,c12) of 
CLA (marketed as Clarinol
®
 and Tonalin
®
), the NDA Panel considered that the observed increase in 
plasma and urinary concentrations of isoprostanes, which may indicate an increase in lipid 
peroxidation, and the increase in some markers of subclinical inflammation (i.e. 15-keto-
dihydroprostaglandin F2α and possibly C-reactive protein) associated with CLA consumption, together 
with the limited data available on the effects of CLA on vascular function, may indicate a potential 
for vascular damage (i.e. atherosclerosis) in the longer term. 
In this context, the applicant was requested to clarify how a reduction in body fat mass, when 
accompanied by an increase in markers of lipid peroxidation and subclinical inflammation, could be 
considered a beneficial physiological effect for the target population. In reply, the applicant argued 
that “Clarinol® and Tonalin® are intended to be used for a period of 6 months to achieve the claimed 
effect, and that within this dosing duration, there are no adverse effects on insulin sensitivity/glucose 
metabolism, blood lipids, lipid peroxidation, or subclinical inflammation within the target population 
(i.e. otherwise healthy overweight or class I obese adults)”. 
The Panel notes that, although consumption of the equimolar isomeric mixture of CLA for six months 
was considered safe for normal-weight, overweight and obese non-diabetic subjects, an increase in 
lipid peroxidation and in markers of inflammation was observed within a time frame of six months. 
The Panel also notes that the applicant did not provide evidence or a rationale for how a reduction in 
body fat mass, when accompanied by an increase in markers of lipid peroxidation and inflammation, 
could be considered a beneficial physiological effect for the target population. 
The Panel considers that the information provided by the applicant does not establish that a reduction 
in body fat mass, when accompanied by an increase in markers of lipid peroxidation and 
inflammation, is a beneficial physiological effect for the target population. 
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The Panel concludes that a cause and effect relationship has not been established between the 
consumption of an equimolar mixture of the CLA isomers c9,t11 and t10,c12, marketed under the 
trade names of Clarinol
®
 and Tonalin
®
, and a beneficial physiological effect. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 19/08/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 On 12/09/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide clarification. 
 On 17/09/2014, EFSA received the clarification as submitted by the applicant. 
 The scientific evaluation procedure started on 17/09/2014. 
 On 16/10/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application and the clock 
was stopped on 27/10/2014, in compliance with Article 18(3) of Regulation (EC) No 
1924/2006. 
 On 07/11/2014, EFSA received the applicant’s reply and the clock was restarted (on 
10/11/2014), in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 During its meeting on 11/12/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to an equimolar 
mixture (marketed as Clarinol
®
 and Tonalin
®
) of the CLA isomers c9,t11 and t10,c12 and 
“contributes to a reduction in body fat mass”. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: an equimolar mixture (marketed 
under the trade names of Clarinol
®
 and Tonalin
®
) of the CLA isomers c9,t11 and t10,c12 and 
“contributes to a reduction in body fat mass”. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of an equimolar mixture of the CLA isomers c9,t11 and t10,c12, a positive assessment of 
its safety, nor a decision on whether an equimolar mixture of the CLA isomers c9,t11 and t10,c12 is, 
or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicants’ name and address 
BASF BE, Global Segment Management/Human Nutrition, ENS/H, Carl Bosch Strasse 38, 67056 
Ludwigshafen, Germany. 
Stepan Lipid Nutrition, Museumlaan 16, 1541 LP Koog aan de Zaan, The Netherlands. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is Clarinol
®
 or Tonalin
®
, 
which provide a minimum of 78 % of total fatty acids as conjugated linoleic acid (CLA) and a 
minimum of 74 % of total fatty acids as the two CLA isomers c9,t11 and t10,c12 at a ratio of 50:50, in 
either triacylglycerol or free fatty acid form. 
Health relationship as claimed by the applicant 
According to the applicant, the consumption of Clarinol
®
 or Tonalin
®
 contributes to a reduction in 
body fat mass. 
In relation to the proposed mechanism by which the food would exert the claimed effect, the applicant 
claimed that Clarinol
®
 or Tonalin
®
 increase lipolysis and the beta-oxidation of fatty acids, as well as 
energy expenditure and metabolic rate. The proposed underlying mechanism is that the CLA isomers 
in Clarinol
®
 or Tonalin
® 
act as peroxisome proliferator-activated receptor (PPAR)-γ antagonists 
(Kennedy et al., 2008), which would lead to the activation of adenosine monophosphate-activated 
protein kinase (AMPK) (Jiang et al., 2012). The activation of AMPK increases the rate of lipolysis 
and upregulates uncoupling proteins (UCPs), which use energy sources to generate heat (Evans et al., 
2002; Zhai et al., 2010). 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Consumption of Clarinol® or 
Tonalin
®
 contributes to a reduction in body fat mass”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 4.0 to 4.5 g Clarinol
®
 or Tonalin
®
 per day. According to the 
applicant, this amount can reasonably be consumed as part of a balanced diet. The duration required 
to see an effect should be set at six months. 
The target population proposed by the applicant is healthy overweight or class I obese male and 
female adults, either sedentary or physically active, who wish to reduce their body fat mass. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is Clarinol
®
 or Tonalin
®
, which are oils rich in 
conjugated linoleic acid (CLA). 
CLA refers to a group of positional and geometric isomers of linoleic acid that are characterised by 
the presence of conjugated dienes. CLA is a natural, but minor, component of fats from ruminant 
Equimolar isomeric mixture of CLA and a reduction in body fat mass 
 
 
EFSA Journal 2015;13(1):3953 8 
animals and is present in the human diet primarily in meat and dairy products. In nature, the most 
abundant isomer is cis-9,trans-11 (c9,t11). 
Clarinol
®
 or Tonalin
®
 provide a minimum of 78 % of total fatty acids as CLA and a minimum of 74 % 
of total fatty acids as the two CLA isomers c9,t11 and trans-10,cis-12 (t10,c12), which are present at 
an equimolar (1:1) ratio. These isoforms can be measured in foods by established methods. Clarinol
®
 
and Tonalin
®
 have been characterised (EFSA NDA Panel, 2010a, b). 
An overview of the manufacturing process, batch-to-batch variability and information regarding 
stability of the oils were provided. 
The Panel considers that the food, an equimolar mixture of the two CLA isomers c9,t11 and t10,c12, 
marketed under the trade names of Clarinol
®
 and Tonalin
®
, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “contributes to a reduction in body fat mass”. The 
target population proposed by the applicant is “healthy overweight or class I obese male and female 
adults, either sedentary or physically active, who wish to reduce their body fat mass”. 
The Panel notes that an excess of body fat, and in particular of abdominal fat, is associated with 
adverse health effects, e.g. impaired glucose tolerance, dyslipidaemia and high blood pressure. The 
Panel also notes that a reduction of body fat through energy (i.e. caloric) restriction and/or through an 
increase in energy expenditure (i.e. physical exercise/activity) is generally accompanied by an 
improvement of such adverse health effects. In this context, the Panel considers that a reduction of 
body fat, with or without a reduction of body weight, is a beneficial physiological effect for 
overweight subjects in the general population. 
In previous assessments on the safety of an equimolar isomer mixture (c9,t11 and t10,c12) of CLA 
(marketed as Clarinol
®
 and Tonalin
®
) as a Novel Food ingredient (EFSA NDA Panel, 2010a, b, 2012), 
the NDA Panel considered that “the administration of the 1:1 isomer mixture of CLA to normal-
weight, overweight and obese non-diabetic subjects does not appear to have adverse effects on insulin 
sensitivity, blood glucose control or liver function at the proposed conditions of use up to six months. 
[…] However, the observed increase in plasma and urinary concentrations of isoprostanes, which may 
indicate an increase in lipid peroxidation, and the increase in some markers of subclinical 
inflammation (i.e. 15-keto-dihydroprostaglandin F2α and possibly C-reactive protein) associated with 
CLA consumption, together with the limited data available on the effects of CLA on vascular 
function, may indicate a potential for vascular damage (i.e. atherosclerosis) in the longer term”. 
In this context, the applicant was requested to clarify how a reduction in body fat mass, when 
accompanied by an increase in markers of lipid peroxidation and subclinical inflammation, could be 
considered a beneficial physiological effect for the target population. In reply, the applicant argued 
that “Clarinol® and Tonalin® are intended to be used for a period of 6 months to achieve the claimed 
effect, and that within this dosing duration, there are no adverse effects on insulin sensitivity/glucose 
metabolism, blood lipids, lipid peroxidation, or subclinical inflammation within the target population 
(i.e. otherwise healthy overweight or class I obese adults)”. 
The Panel notes that, although consumption of the equimolar isomeric mixture of CLA for six months 
was considered safe for normal-weight, overweight and obese non-diabetic subjects, an increase in 
lipid peroxidation and in markers of inflammation was observed within a time frame of six months. 
The Panel also notes that the applicant did not provide evidence or a rationale for how a reduction in 
body fat mass, when accompanied by an increase in markers of lipid peroxidation and inflammation, 
could be considered a beneficial physiological effect for the target population. 
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The Panel considers that the information provided by the applicant does not establish that a reduction 
in body fat mass, when accompanied by an increase in markers of lipid peroxidation and 
inflammation, is a beneficial physiological effect for the target population. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of an equimolar mixture of the CLA isomers c9,t11 and t10,c12, marketed under the 
trade names of Clarinol
®
 and Tonalin
®
, and a beneficial physiological effect. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, an equimolar mixture of the CLA isomers c9,t11 and t10,c12, marketed under the 
trade names of Clarinol
®
 and Tonalin
®
, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “contributes to a reduction in body fat mass”. 
The target population proposed by the applicant is “healthy overweight or class I obese male 
and female adults, either sedentary or physically active, who wish to reduce their body fat 
mass”. The information provided by the applicant does not establish that a reduction in body 
fat mass, when accompanied by an increase in markers of lipid peroxidation and 
inflammation, is a beneficial physiological effect for the target population. 
 A cause and effect relationship has not been established between the consumption of an 
equimolar mixture of the CLA isomers c9,t11 and t10,c12, marketed under the trade names of 
Clarinol
®
 and Tonalin
®
, and a beneficial physiological effect. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Clarinol
®
 or Tonalin
®
 and contributes to a reduction in body fat mass 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (EFSA-Q-2014-00580, Claim serial No: 
0426_NL). August 2014. Submitted by BASF SE and Stepan Lipid Nutrition. 
REFERENCES 
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010a. Scientific 
Opinion on the safety of “conjugated linoleic acid (CLA)-rich oil” (Cognis) as a Novel Food 
ingredient. EFSA Journal 2010;8(5):1600, 43 pp. doi:10.2903/j.efsa.2010.1600 
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010b. Scientific 
Opinion on the safety of “conjugated linoleic acid (CLA)-rich oil” (Lipid Nutrition) as a Novel 
Food ingredient. EFSA Journal 2010;8(5):1601, 41 pp. doi:10.2903/j.efsa.2010.1601 
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012. Statement on 
the safety of the “conjugated linoleic acid (CLA)-rich oils” Clarinol® and Tonalin TG 80 as Novel 
Food ingredients. EFSA Journal 2012;10(5):2700, 15 pp. doi:10.2903/j.efsa.2012.2700 
Evans M, Lin X, Odle J and McIntosh M, 2002. Trans-10,cis-12 conjugated linoleic acid increases 
fatty acid oxidation in 3T3-L1 preadipocytes. Journal of Nutrition, 132, 450–455. 
Jiang S, Wang W, Miner J and Fromm M, 2012. Cross regulation of sirtuin 1, AMPK, and PPARγ in 
conjugated linoleic acid treated adipocytes. PLoS One 7, e48874. 
doi:10.1371/journal.pone.0048874 
Equimolar isomeric mixture of CLA and a reduction in body fat mass 
 
 
EFSA Journal 2015;13(1):3953 10 
Kennedy A, Chung S, LaPoint K, Fabiyi O and McIntosh MK, 2008. Trans-10,cis-12 conjugated 
linoleic acid antagonizes ligand-dependent PPARgamma activity in primary cultures of human 
adipocytes. Journal of Nutrition, 138, 455–461. 
Zhai JJ, Liu ZL, Li JM, Chen JP, Jiang L, Wang DM, Yuan J, Shen JG, Yang DP and Chen JQ, 2010. 
Different mechanisms of cis-9, trans-11 and trans-10, cis-12 conjugated-linoleic acid affecting 
lipid metabolism in 3T3-L1 cells. Journal of Nutritional Biochemistry, 21, 1099–1105. 
Equimolar isomeric mixture of CLA and a reduction in body fat mass 
 
 
EFSA Journal 2015;13(1):3953 11 
ABBREVIATIONS 
CLA conjugated linoleic acid 
c9,t11 cis-9,trans-11 
t10,c12 trans-10,cis-12 
